Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs. / Prokopyeva, E. A.; Kurskaya, O. G.; Solomatina, M. V. и др.
в: Jurnal Infektologii, Том 11, № 4, 01.04.2019, стр. 53-64.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs
AU - Prokopyeva, E. A.
AU - Kurskaya, O. G.
AU - Solomatina, M. V.
AU - Sobolev, I.
AU - Murashkina, T.
AU - Derko, A.
AU - Korchagina, K. V.
AU - Yunusova, A. Y.
AU - Alekseev, A. Y.
AU - Shestopalov, A.
AU - Sysolyatin, S. V.
AU - Vorozhtsov, A. B.
AU - Vaizova, O.
AU - Sherstoboev, E. Y.
AU - Sharshov, K.
AU - Dygai, A.
N1 - Прокопьева Е.А., Курская О.Г., Соломатина М.В., Соболев И.А., Мурашкина Т.А., Дёрко А.А., Корчагина К.В., Юнусова А.Ю., Алексеев А.Ю., Шестопалов А.М., Сысолятин С.В., Ворожцов А.Б., Ваизова О.Е., Шерстобоев Е.Ю., Шаршов К.А., Дыгай А.М. Вариант вируса гриппа в, адаптированный к мышам, для изучения лечебной и профилактической эффективности противовирусных препаратов in vitro и in vivo // Журнал инфектологии. - 2019. - Т. 11. - № 4. С. 53-64
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.
AB - Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.
KW - Adapted influenza virus B
KW - Antiviral drug (oseltamivir ethoxysuccinate
KW - Influenza model
KW - Tamiflu®)
UR - http://www.scopus.com/inward/record.url?scp=85084032063&partnerID=8YFLogxK
U2 - 10.22625/2072-6732-2019-11-4-53-64
DO - 10.22625/2072-6732-2019-11-4-53-64
M3 - Article
AN - SCOPUS:85084032063
VL - 11
SP - 53
EP - 64
JO - Jurnal Infektologii
JF - Jurnal Infektologii
SN - 2072-6732
IS - 4
ER -
ID: 24228203